The filing confirms the CEO is actively selling under a pre-arranged plan, not a discretionary sale. The plan was adopted months before the filing date, so the sale is not a reaction to recent events. Monitor for any subsequent Form 4 filings to see if the sale is executed, and watch for any changes in the company's guidance or earnings outlook.
Price Chart
Executive Summary
CEO Derek Maetzold filed a Form 144 notice of intent to sell 28,992 shares of Castle Biosciences common stock, with an estimated aggregate market value of approximately $1,062,557 as of October 5, 2026. The sales are part of a Rule 10b5-1 trading plan adopted on June 2, 2026, covering shares held directly and through trusts. While the CEO's planned sale is notable, the pre-arranged plan structure reduces the signaling concern of a discretionary insider sale.
Key Facts
- CEO Derek Maetzold filed Form 144 to sell 28,992 shares of common stock.
- Estimated aggregate market value of the proposed sale is approximately $1,062,557.
- Sales are being made pursuant to a Rule 10b5-1 trading plan dated June 2, 2026.
- Shares are to be sold through Goldman Sachs & Co. LLC on behalf of Derek Maetzold.
- The plan covers shares held directly by Derek Maetzold (17,160 shares), the DM 2020 Irrevocable Trust (5,436 shares), and the Maetzold Descendants 2020 Trust (5,396 shares).
- The filing date is October 5, 2026.
- The plan was adopted on June 2, 2026.
- The filing includes a large number of prior sales from July through September 2026, indicating a pattern of consistent selling under the plan.
Financial Impact
CEO's proposed sale of ~$1.06M worth of shares is a moderate proportion of his holdings, but the 10b5-1 plan structure reduces the typical insider signal. The total number of shares to be sold is 28,992 shares.
Risk Factors
- CEO selling under a 10b5-1 plan reduces the signal of a discretionary insider sale.
- The plan was adopted months before the filing date, so the sale is not a reaction to recent events.
- The filing includes a large number of prior sales from July through September 2026, indicating a pattern of consistent selling under the plan.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001958244-26-000640 |
| Document: 0001958244-26-000640-index.html | 0001958244-26-000640 |
| Document: 0001958244-26-000640.txt | 0001958244-26-000640 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Insider Cluster | $33.19 $33.08 | ▼ −0.33% | ▲ +0.19% | $33.30 (+0.33%) |
Oct 5, 2026 21d ago | 144 | $33.36 $33.00 | ▼ −1.08% | ▼ −0.84% | $33.30 (−0.18%) |
Oct 5, 2026 21d ago | Insider Cluster | $33.36 $33.00 | ▼ −1.08% | ▼ −0.84% | $33.30 (−0.18%) |
Sep 23, 2026 4w ago | Insider Cluster | $35.19 $35.81 | ▼ −1.76% | ▼ −1.22% | $33.30 (+5.37%) |
Sep 16, 2026 5w ago | Insider Cluster | $36.78 $35.34 | ▼ −3.92% | ▼ −4.04% | $33.30 (−9.46%) |
Sep 11, 2026 6w ago | 144 | $33.44 $35.50 | ▲ +6.16% | ▲ +6.62% | $33.30 (−0.42%) |
Sep 3, 2026 7w ago | Insider Cluster | $32.91 $32.76 | ▲ +0.46% | ▼ −0.09% | $33.30 (−1.19%) |
Sep 2, 2026 7w ago | Insider Cluster | $32.65 $32.91 | ▲ +0.80% | ▲ +1.18% | $33.30 (+1.99%) |
Sep 1, 2026 7w ago | Insider Cluster | $33.42 $32.65 | ▼ −2.30% | ▼ −3.35% | $33.30 (−0.36%) |
Aug 27, 2026 8w ago | Insider Cluster | $33.50 $33.03 | ▼ −1.40% | ▼ −1.10% | $33.30 (−0.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers